MAPT and Alzheimer disease: Furthermore, data on the relationships among neuropsychological and neuroimaging findings in the AD spectrum and cerebrospinal fluid (CSF) biomarkers (beta-Amyloid 1-42 – Aβ1-42 - and tau protein) of AD pathology are inconclusive across studies [40].